Anti-il-31 antibody, pharmaceutical composition thereof and use thereof

WO2026017189A3 Publication Date: 2026-03-12BIOTHEUS INC
5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/122110
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-19
Filing Date
2025-09-18
Publication Date
2026-03-12

AI Technical Summary

Technical Problem

Current technology has not yet developed effective IL-31-targeting antibodies for the treatment of itching caused by autoimmune diseases, especially itching associated with refractory atopic dermatitis.

Method used

An antibody specifically targeting interleukin-31 (IL-31) has been developed, containing specific heavy chain variable regions and light chain variable regions. It can bind to human and cynomolgus monkey IL-31 with high affinity, block the binding of IL-31 to its receptor IL-31RA, and reduce or eliminate downstream STAT3 phosphorylation signaling in cells.

Benefits of technology

The antibody significantly inhibited IL-31-induced pruritus in animal models, providing a novel IL-31-targeting antibody for the treatment of pruritus, which can rapidly and significantly reduce pruritus and improve patients' sleep and quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine, and relates to an anti-IL-31 antibody, a pharmaceutical composition thereof and the use thereof. Specifically, the present invention relates to an anti-IL-31 monoclonal antibody or an antigen-binding fragment thereof. The antibody of the present invention has a high affinity for human IL-31 and cynomolgus monkey IL-31, can effectively block the binding of IL-31 to the IL-31RA receptor thereof, can reduce or eliminate intracellular downstream STAT3 phosphorylation signals and significantly inhibit pruritus caused by IL-31, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art